Detalles de la búsqueda
1.
Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
Mol Ther
; 29(2): 597-610, 2021 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33309883
2.
Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study.
Clin Immunol
; 197: 68-76, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30205177
3.
Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.
Mol Genet Metab
; 125(3): 217-227, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30146451
4.
PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.
Toxicol Pathol
; 43(7): 959-83, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26239651
5.
Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.
J Virol
; 86(22): 12105-14, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22933284
6.
AAV9-NGLY1 gene replacement therapy improves phenotypic and biomarker endpoints in a rat model of NGLY1 Deficiency.
Mol Ther Methods Clin Dev
; 27: 259-271, 2022 Dec 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36320418
7.
Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus.
J Virol
; 84(21): 11200-9, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20702624
8.
Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors.
J Virol
; 84(7): 3576-85, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20071586
9.
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.
J Infect Dis
; 201(7): 1045-53, 2010 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20170371
10.
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria.
Clin Transl Sci
; 14(5): 1894-1905, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34057292
11.
High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.
J Gen Virol
; 91(Pt 1): 250-8, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19793903
12.
Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies.
J Virol
; 83(15): 7728-38, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19474108
13.
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection.
J Virol
; 83(7): 3288-97, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19129448
14.
The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy.
Mol Ther Methods Clin Dev
; 13: 440-452, 2019 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31193016
15.
2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62).
Bioanalysis
; 11(24): 2207-2244, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31820675
16.
Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials.
EBioMedicine
; 37: 366-373, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30366815
17.
Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
Clin Ther
; 39(1): 118-129.e3, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27955919
18.
Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome.
J Immunol Methods
; 440: 41-51, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27789297
19.
Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
Clin Ther
; 37(5): 1012-1021.e6, 2015 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25487082
20.
Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.
AIDS
; 16(17): 2342-4, 2002 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-12441810